Half a decade ago, Moderna (MRNA) was a name that barely resonated in pharmaceutical circles. Focused on DNA-based drugs and vaccines, the company lingered on the periphery, largely overlooked by investors wary of speculative biotechnology ventures. Then came the seismic shock of…
Today: 5. Nov, 2024